… Plenary Session P4: New developments in the field of CAR T cell therapy Wednesday, March 17, 16:15 - 17:30, Auditorium … 1 This three-part plenary session on new developments in CAR therapy will be opened by Dr Marcela Maus of Harvard … EBMT 2021 Annual Meeting - New developments in CAR therapy …

… CAR-T cell outcomes in patients with comorbidities …

… Thrombotic microangiopathy (TMA) after CAR-T cell therapy …

… piece of artwork from patients recovered through CAR-T cell therapy. We then get to hear a panel discussion from … with CRS and ICANS in DLBCL patients undergoing CAR-T cell therapy. Key messages: standardise hospital practices, … as well as learning about treosulfan-based conditioning, CAR-T cell therapy and toxicities, and haematopoietic stem …

… a joint meeting focusing on common research themes of CAR-T in multiple myeloma (MM). A keynote lecture was given by … results in patients with MM and that potentially moving CAR-T cells and bispecifics to earlier lines over the natural …

… Horgan, senior clinical research fellow in Paediatric BMT, CAR-T and stem cell gene therapy at Royal Manchester Children's … world with different resources and health systems, and a CAR-T roundtable discussion.”  “The second trainee session is …

… Garderet (Paris) there was a debate on the placement of CAR-T in the autoHCT algorithm for myeloma. Nico Gagelmann … France) gave a presentation on whether the advent of CAR-T for CLL would completely displace allo-HCT. Professor …

… CVC and anticoagulation survey in HCT and CAR-T …

… collaborations across stakeholders in the field of CAR T-cell therapies. The selection committee was composed by … on the feasibility, safety and efficacy of anti-CD19 CAR-T cells in acute lymphoblastic leukemia ” (co-PIs: …

… chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma Marta Canelo-Vilaseca et …   Indications for haematopoietic cell transplantation and CAR-T for haematological diseases, solid tumours and immune …